Article

Choice Between Daily, On-Demand PrEP Regimens Could Be Offered to Men with Lower Risk of HIV

Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk.

A choice between daily or on-demand pre-exposure prophylaxis (PrEP) regimens could be offered to men who have sex with men (MSM) with a lower risk of HIV, according to a study published in The Lancet.

The ANRS IPERGAY trial found that on-demand PrEP with oral tenofovir disoproxil fumarate (TDF) plus emtricitabine was associated with an 86% relative reduction of HIV-1 incidence compared with placebo among MSM at high risk of HIV. Researchers in this study aimed to investigate whether on-demand PrEP was similarly effective among individuals with lower exposure to HIV risk.

The study included 400 participants randomly assigned to receive PrEP in a fixed-dose combination of 300 mg TDF and 200 mg emtricitabine per pill or placebo. The primary endpoint was the diagnosis of HIV-1 infection.

Participants were interviewed at each visit to assess the pattern of PrEP use. All participants enrolled in the modified intention-to-treat population of the double-blind phase of the ANRS IPERGAY trial were eligible for this post-hoc analysis.

Two-hundred seventy participants had at least 1 period of less frequent sexual intercourse with high PrEP adherence during the study, representing 134 person-years of follow-up and 31% of the total study follow-up. Six HIV-1 infections were diagnosed in the placebo group and none were diagnosed in the TDF plus emtricitabine arm, with a relative reduction of HIV incidence of 100%.

Based on the study findings, the study authors noted that a choice between daily or on-demand PrEP regimens could be offered to MSM who have less frequent sexual intercourse.

Reference

Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. The Lancet. Published November 26, 2019. DOI: https://doi.org/10.1016/S2352-3018(19)30341-8. Accessed December 18, 2019.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication